Principal Investigator
Charles Mitchell
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221018
Clinical Trial Summary
Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Nicolette Gomez
Phone Number
+1 (305) 2434447
Email
n.gomez8@umiami.edu